1iyt Citations

Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain.

Abstract

The major components of neuritic plaques found in Alzheimer disease (AD) are peptides known as amyloid beta-peptides (Abeta), which derive from the proteolitic cleavage of the amyloid precursor proteins. In vitro Abeta may undergo a conformational transition from a soluble form to aggregated, fibrillary beta-sheet structures, which seem to be neurotoxic. Alternatively, it has been suggested that an alpha-helical form can be involved in a process of membrane poration, which would then trigger cellular death. Conformational studies on these peptides in aqueous solution are complicated by their tendency to aggregate, and only recently NMR structures of Abeta-(1-40) and Abeta-(1-42) have been determined in aqueous trifluoroethanol or in SDS micelles. All these studies hint to the presence of two helical regions, connected through a flexible kink, but it proved difficult to determine the length and position of the helical stretches with accuracy and, most of all, to ascertain whether the kink region has a preferred conformation. In the search for a medium which could allow a more accurate structure determination, we performed an exhaustive solvent scan that showed a high propensity of Abeta-(1-42) to adopt helical conformations in aqueous solutions of fluorinated alcohols. The 3D NMR structure of Abeta-(1-42) shows two helical regions encompassing residues 8-25 and 28-38, connected by a regular type I beta-turn. The surprising similarity of this structure, as well as the sequence of the C-terminal moiety, with those of the fusion domain of influenza hemagglutinin suggests a direct mechanism of neurotoxicity.

Reviews - 1iyt mentioned but not cited (14)

  1. Amyloid beta: structure, biology and structure-based therapeutic development. Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, Xu HE. Acta Pharmacol Sin 38 1205-1235 (2017)
  2. The amyloid-beta precursor protein: integrating structure with biological function. Reinhard C, Hébert SS, Hébert SS, De Strooper B. EMBO J 24 3996-4006 (2005)
  3. Alzheimer's disease: which type of amyloid-preventing drug agents to employ? Jang H, Connelly L, Arce FT, Ramachandran S, Lal R, Kagan BL, Nussinov R. Phys Chem Chem Phys 15 8868-8877 (2013)
  4. Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases. Gonçalves PB, Sodero ACR, Cordeiro Y. Biomolecules 11 767 (2021)
  5. Mamma Mia, P-glycoprotein binds again. Callaghan R, Gelissen IC, George AM, Hartz AMS. FEBS Lett 594 4076-4084 (2020)
  6. Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer's Disease. Fulop T, Tripathi S, Rodrigues S, Desroches M, Bunt T, Eiser A, Bernier F, Beauregard PB, Barron AE, Khalil A, Plotka A, Hirokawa K, Larbi A, Bocti C, Laurent B, Frost EH, Witkowski JM. Neuropsychiatr Dis Treat 17 1311-1339 (2021)
  7. Aducanumab-Hope or Disappointment for Alzheimer's Disease. Wojtunik-Kulesza K, Rudkowska M, Orzeł-Sajdłowska A. Int J Mol Sci 24 4367 (2023)
  8. Alzheimer's disease--a panorama glimpse. Zhao LN, Lu L, Chew LY, Mu Y. Int J Mol Sci 15 12631-12650 (2014)
  9. Structural biology of cell surface receptors implicated in Alzheimer's disease. Hermans SJ, Nero TL, Morton CJ, Gooi JH, Crespi GAN, Hancock NC, Gao C, Ishii K, Markulić J, Parker MW. Biophys Rev 14 233-255 (2022)
  10. The Hidden Role of Non-Canonical Amyloid β Isoforms in Alzheimer's Disease. Busch L, Eggert S, Endres K, Bufe B. Cells 11 3421 (2022)
  11. Computer Aided Drug Design Methodologies with Natural Products in the Drug Research Against Alzheimer's Disease. de Sousa NF, Scotti L, de Moura ÉP, Dos Santos Maia M, Rodrigues GCS, de Medeiros HIR, Lopes SM, Scotti MT. Curr Neuropharmacol 20 857-885 (2022)
  12. Current understanding of metal-dependent amyloid-β aggregation and toxicity. Yi Y, Lim MH. RSC Chem Biol 4 121-131 (2023)
  13. Big versus small: The impact of aggregate size in disease. Hnath B, Chen J, Reynolds J, Choi E, Wang J, Zhang D, Sha CM, Dokholyan NV. Protein Sci 32 e4686 (2023)
  14. The Pathological Effects of Circulating Hydrophobic Bile Acids in Alzheimer's Disease. Ehtezazi T, Rahman K, Davies R, Leach AG. J Alzheimers Dis Rep 7 173-211 (2023)

Articles - 1iyt mentioned but not cited (121)



Reviews citing this publication (25)

  1. Amyloid-beta aggregation. Finder VH, Glockshuber R. Neurodegener Dis 4 13-27 (2007)
  2. Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis. Harauz G, Ishiyama N, Hill CM, Bates IR, Libich DS, Farès C. Micron 35 503-542 (2004)
  3. The interplay of catalysis and toxicity by amyloid intermediates on lipid bilayers: insights from type II diabetes. Hebda JA, Miranker AD. Annu Rev Biophys 38 125-152 (2009)
  4. Implications of peptide assemblies in amyloid diseases. Ke PC, Sani MA, Ding F, Kakinen A, Javed I, Separovic F, Davis TP, Mezzenga R. Chem Soc Rev 46 6492-6531 (2017)
  5. Antimicrobial properties of amyloid peptides. Kagan BL, Jang H, Capone R, Teran Arce F, Ramachandran S, Lal R, Nussinov R. Mol Pharm 9 708-717 (2012)
  6. From Alzheimer to Huntington: why is a structural understanding so difficult? Temussi PA, Masino L, Pastore A. EMBO J 22 355-361 (2003)
  7. Structure and function of amyloid in Alzheimer's disease. Morgan C, Colombres M, Nuñez MT, Inestrosa NC. Prog Neurobiol 74 323-349 (2004)
  8. Direct binding of cholesterol to the amyloid precursor protein: An important interaction in lipid-Alzheimer's disease relationships? Beel AJ, Sakakura M, Barrett PJ, Sanders CR. Biochim Biophys Acta 1801 975-982 (2010)
  9. Coarse-grained models for protein aggregation. Wu C, Shea JE. Curr Opin Struct Biol 21 209-220 (2011)
  10. Strategies for the inhibition of protein aggregation in human diseases. Bartolini M, Andrisano V. Chembiochem 11 1018-1035 (2010)
  11. Disordered amyloidogenic peptides may insert into the membrane and assemble into common cyclic structural motifs. Jang H, Arce FT, Ramachandran S, Kagan BL, Lal R, Nussinov R. Chem Soc Rev 43 6750-6764 (2014)
  12. What is the dominant Abeta species in human brain tissue? A review. Gregory GC, Halliday GM. Neurotox Res 7 29-41 (2005)
  13. D-amino acid-based peptide inhibitors as early or preventative therapy in Alzheimer disease. Kumar J, Sim V. Prion 8 119-124 (2014)
  14. Functional Reciprocity of Amyloids and Antimicrobial Peptides: Rethinking the Role of Supramolecular Assembly in Host Defense, Immune Activation, and Inflammation. Lee EY, Srinivasan Y, de Anda J, Nicastro LK, Tükel Ç, Wong GCL. Front Immunol 11 1629 (2020)
  15. Towards a true protein movie: a perspective on the potential impact of the ensemble-based structure determination using exact NOEs. Vögeli B, Orts J, Strotz D, Chi C, Minges M, Wälti MA, Güntert P, Riek R. J Magn Reson 241 53-59 (2014)
  16. Strategies for dealing with conformational sampling in structural calculations of flexible or kinked transmembrane peptides. Rainey JK, Fliegel L, Sykes BD. Biochem Cell Biol 84 918-929 (2006)
  17. Apolipoprotein Abeta: black sheep in a good family. Kontush A. Brain Pathol 14 433-447 (2004)
  18. Structural Studies Providing Insights into Production and Conformational Behavior of Amyloid-β Peptide Associated with Alzheimer's Disease Development. Urban AS, Pavlov KV, Kamynina AV, Okhrimenko IS, Arseniev AS, Bocharov EV. Molecules 26 2897 (2021)
  19. Structure and Function of Alzheimer's Amyloid βeta Proteins from Monomer to Fibrils: A Mini Review. Agrawal N, Skelton AA. Protein J 38 425-434 (2019)
  20. Arginine and Arginine-Rich Peptides as Modulators of Protein Aggregation and Cytotoxicity Associated With Alzheimer's Disease. Mamsa SSA, Meloni BP. Front Mol Neurosci 14 759729 (2021)
  21. When "IUPs" were "BAPs": How to study the nonconformation of intrinsically unfolded polyaminoacid chains. Pastore A, Temussi P. Biopolymers 100 592-600 (2013)
  22. Impact of a discordant helix on β-amyloid structure, aggregation ability and toxicity. Chen YC. Eur Biophys J 46 681-687 (2017)
  23. Physical Chemistry of the Protein Backbone: Enabling the Mechanisms of Intrinsic Protein Disorder. Drake JA, Pettitt BM. J Phys Chem B 124 4379-4390 (2020)
  24. Amyloid beta and its naturally occurring N-terminal variants are potent activators of human and mouse formyl peptide receptor 1. Busch L, Al Taleb Z, Tsai YL, Nguyen VTT, Lu Q, Synatschke CV, Endres K, Bufe B. J Biol Chem 298 102642 (2022)
  25. Amyloidogenicity at a Distance: How Distal Protein Regions Modulate Aggregation in Disease. Lucato CM, Lupton CJ, Halls ML, Ellisdon AM. J Mol Biol 429 1289-1304 (2017)

Articles citing this publication (188)